Close Menu

More articles about Business News

Spectrum Solutions' specimen collection device is used with SARS-CoV-2 saliva tests from DxTerity Diagnostics and RUCDR Infinite Biologics.

The Seattle-based genomics technology firm said it intends to use the funds for working capital and general corporate purposes.

The single-molecule sequencing firm is skipping a beta testing program for its new sequencer, which should be available by the end of the year.

Investigators are conducting a prospectively designed, retrospective study of archived material from the NeoTRIPaPDL1 triple negative breast cancer trial.

The company's Advanta Dx SARS-CoV-2 RT-PCR assay received Emergency Use Authorization from the US Food and Drug Administration in August.

Seasun Biomaterials' test is designed to detect SARS-CoV-2 RNA, while Zeus Scientific's test detects IgG antibodies against the virus.

The company said it provided approximately 21,800 total AlloSure and AlloMap patient results during the quarter.

The companies are currently working together to commercialize their respective products including genetic tests for type 2 diabetes and gestational diabetes risk.

The test, called CovidNudge, is a version of DnaNudge's consumer DNA test that has been reengineered for the point-of-care detection of SARS-CoV-2.

The company expects product and service revenue totaling $30.1 million, driven by higher instrument revenue, offset by declining consumables revenue.

The product uses spin columns to extract high molecular weight DNA with an average length of 100 kb or more from animal and bacterial cells.

The funding will help the San Francisco-based firm apply low-depth NGS as it builds diagnostic tests to aid therapy selection in more diverse populations.

BioFire's test is designed to detect and differentiate between SARS-CoV-2 and other respiratory pathogens, while UMass Medical's test is only for SARS-CoV-2.

The deals give 10x Genomics control of a combined 110 patents covering in situ analysis methods that the firm says will complement its existing platforms.

The company licensed nasopharyngeal swab and toehold switch molecular detection technologies from the Wyss Institute to develop SARS-CoV-2 diagnostics.

The merger brings tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings.

Pages

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.